Abstract library

42 results for "tolerability".
#1540 FOLFOX Chemotherapy: Efficacy and Tolerability in Advanced Digestive Neuroendocrine Neoplasms (NENs)
Introduction: FOLFOX has been poorly investigated in digestive NEN (DNENs), mostly in small cohorts.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Arianna Dal Buono
#1417 Everolimus (EVE) Safety Profile in Patients (pts) with Advanced G1-G2 Neuroendocrine Tumours (NETs) from Daily Clinical Practice
Introduction: EVE has shown an overall favourable and well-characterized safety profile in randomized studies including advanced G1-G2 NETs. However, few data outside regulatory trials are available.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: MD PhD Ana Custodio
#1759 Safety and Tolerability of "Ready-to-Use" (SOMAKIT TOC®) 68Ga-DOTA0-Tyr3-Octreotide (68Ga-DOTATOC) for Injection in Patients with Proven Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)
Introduction: 68Ga-DOTATOC (PET) has superior diagnostic performance than Octreoscan (SPECT) in patients with GEP-NETs.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Angela Lamarca
Keywords: SomaKit, DOTATOC, GEP-NET
#568 Efficacy of Everolimus and Tolerability with Long-Term Use
Introduction: Predictors of response to Everolimus in neuroendocrine tumors and long-term safety data are lacking.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Maximilian Heetfeld
#1811 Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies
Introduction: Two randomized double-blind (DB) trials demonstrated the efficacy of LAN 120mg/4weeks vs placebo in NETs: PFS improved in metastatic non-functioning intestinal/pancreatic NETs (CLARINET); less rescue medication used for carcinoid syndrome (CS) (ELECT).
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Alexandria T Phan
Keywords: Lanreotide, safety
#891 Metastatic G1-G2 Neuroendocrine Tumors (WDNET) Treated with Sequences of Different Somatostatine Analogs (SSA) - Lanreotide LAR (La), Octreotide LAR (Oc): A Single Center Experience
Introduction: PROMID and CLARINET trials demonstrate an improvement in PFS of SSA v. placebo in WDNET.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Riccardo Marconcini
#42 Chemotherapy in the Treatment of Progressive, Undifferentiated Neuroendocrine Carcinomas: a Single-Center Experience.
Introduction: Treatment of poorly differentiated neuroendocrine tumors (NET) usually includes chemotherapeutic intervention. However, both the rarity and the heterogeneity of the disease have led to relatively few clinical trials. This study evaluated the outcome of two chemotherapy regimens in patients suffering from undifferentiated and histologically confirmed NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Timo Deutschbein
#268 Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas
Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: M.D. Ingrid Holst Olsen
#394 Efficacy of Telotristat Etiprate in Refractory Carcinoid Syndrome: Results of a Randomized, Placebo-controlled, Multicenter Study
Introduction: Diarrhea associated with carcinoid syndrome (CS) has been attributed to excess serotonin. Telotristat etiprate is an oral serotonin synthesis inhibitor that decreases peripheral serotonin production.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Matthew Kulke
#396 Telotristat Etiprate Produces Clinical and Biochemical Responses in Patients with Symptomatic Carcinoid Syndrome: Preliminary Results of an Ongoing Phase 2, Multicenter, Open-label, Serial-ascending, European Study
Introduction: Excess serotonin (5-HT) may cause gastrointestinal (GI) symptoms (e.g., diarrhea) in carcinoid syndrome (CS) patients. Telotristat etiprate is an oral serotonin synthesis inhibitor designed to reduce peripheral 5-HT levels and alleviate GI distress.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Marianne E Pavel